Loading company…
ID 404578051 · FY 2023–2024 · 2 years
Subsidiary of შეზღუდული პასუხისმგებლობის საზოგადოება Quest 100 Biosciences LLC (100.0%)
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Line item | 2023 | 2024 | CAGR |
|---|---|---|---|
| Total Revenue | 1,363 | 3,202 | +134.9% |
| Total COGS | -815 | -403 | -50.5% |
| Gross Profit | 549 | 2,799 | +410.0% |
| Gross Margin | 40.3% | 87.4% | |
| Total Operating Expenses | -598 | -1,971 | +229.4% |
| EBITDA | -50 | 828 | nmf |
| EBITDA Margin | -3.6% | 25.9% | |
| Total D&A | -67 | -146 | +119.5% |
| EBIT / Operating Income | -116 | 682 | nmf |
| Total Interest Income | 9 | 0 | |
| Total Interest Expense | -59 | -65 | +11.1% |
| Total Other Income | 0 | -3 | |
| Profit Before Tax | -166 | 613 | nmf |
| Total Income Tax | 0 | 0 | |
| Net Profit / (Loss) | -50 | 825 | nmf |
| Net Margin | -3.6% | 25.8% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).